Join for free and get access to the buyside
Get insights from the world's most influential hedge fund investors direct to your inbox
- © 2025 Buyside Digest
- Privacy Policy
- Disclaimer
- Sitemap
- Terms of Service
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Keywords/Themes | Theme Commentary | Pitches | Letter |
|---|---|---|---|---|---|---|---|---|---|
| 2024 Q3 | Sep 30, 2024 | Apis Deep Value Fund | 5.8% | - | AMZN, CEG, HNRG, HROW, TLN | Asia, China, Data centers, global, nuclear, Power, value | U.S. power demand growth expected to jump to 2.5% annually through 2030, with data centers accounting for nearly half the demand growth. Data centers could account for 9% of U.S. power demand by 2030, up from 4% in 2023. Hyperscalers like Amazon and Microsoft are signing long-term power purchase agreements at significant premiums to secure reliable power supply. | HNRG TLN |
View |
| 2021 Q2 | Aug 1, 2021 | SRK Capital | - | 59.2% | HROW, NNUP, SGMD.V, TTSH | Concentration, Housing, Medical Devices, small caps, value | HROW SGMD.V TTSH |
View | |
| 2026 Q1 | May 4, 2026 | GROW Funds | 4.2% | 4.2% | ALAB, BUDA, DUOT, HOOD, HROW, ISRG, PAYS, PLTR, PROF, TYGO | AI, Hedging, Iran War, Long/Short, oil, small cap, Solar, Valuations | PROF DUOT TYGO PAYS BUDA |
View | |
| 2025 Q1 | Mar 31, 2025 | NCG Micro Cap Growth Strategy | 14.8% | 14.8% | ACVA, AGX, AGYS, ALHC, ALKT, ARQ, ATRO, CSTL, CVLG, DAVA, DCBO, FLYW, FROG, GDYN, HROW, IRTC, MRTN, NEO, OLO, PAL, PDFS, PYCR, SDHC, SMWB, TNDM | growth, healthcare, Micro Cap, small caps, technology, valuation | NCG emphasizes investing in what they believe are the fastest growing and highest quality companies in America. They maintain focus on fundamental growth drivers of each holding and seek companies that can grow revenue and profits at strong rates in any economic environment. | View | |
| 2021 Q4 | Feb 1, 2022 | SRK Capital | - | 46.7% | HROW, MLC.NE, NNUP, RET-A.V, TTSH | Buybacks, concentrated, small caps, undervalued, value | RET-A.V MLC.NE NNUP TTSH HROW |
View | |
| 2023 Q2 | Aug 31, 2023 | SRK Capital | 0.0% | 17.2% | HGBL, HROW, SGMA, SRDX, VASO | - | View | ||
| 2022 Q4 | Feb 16, 2023 | SRK Capital | 0.0% | 17.2% | HGBL, HROW, JOB, MLC CN | - | View | ||
| 2023 Q4 | Jan 2, 2024 | SRK Capital | 0.0% | 17.2% | HGBL, HROW, ISSC, SGMA, VASO | aerospace, concentrated, Credit Stress, Manufacturing, small caps, SPACs, value | ISSC operates in aerospace with robust double-digit growth and attractive margins, focusing on cockpit and cabin products for business, cargo, and military aircraft. The company completed an acquisition from Honeywell for $36M that nearly doubles earnings for FY24. | SGMA HGBL VASO ISSC |
View |
| Date | Pitch Type | Author | Company | Industry | Sub Industry | Bull / Bear | Stock Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | Fund Letters | SRK Capital | Harrow Health Inc. | Drug Manufacturers - Specialty & Generic | Pharmaceuticals | Bull | NASDAQ | Cataract Surgery, Compounding Pharmacy, Healthcare services, market share, operating leverage, Ophthalmology, pharmaceuticals, Value | View Pitch |
| Jun 15, 2026 | Fund Letters | SRK Capital | Harrow Health Inc. | Drug Manufacturers - Specialty & Generic | Pharmaceuticals | Bull | NASDAQ | Aging Population, Cataract Surgery, Drug Compounder, FDA-Approved Products, Market Leading, operating leverage, Ophthalmic Pharmaceuticals, Pent-up Demand | View Pitch |
| Oct 30, 2025 | Value Investors Club | ppsm920 | Harrow, Inc. | Health Care | Pharmaceuticals | Bull | NASDAQ | Anesthesia, Biosimilars, Ophthalmology, Specialty pharma | View Pitch |
| Sep 16, 2025 | Short Thesis | Bonitas | Harrow Health Inc | Health Care | Pharmaceuticals | Bear | NASDAQ | acquisition, compounding, Ophthalmology, pharma, Regulation | View Pitch |
| Aug 8, 2025 | Seeking Alpha | Quad 7 Capital | Harrow, Inc. | Other | - | Bull | NASDAQ | — | View Pitch |
| Aug 8, 2025 | Seeking Alpha | Michigan Value Investor | Harrow, Inc. | Health Care | Drug Manufacturers - Specialty & Generic | Bull | NASDAQ | — | View Pitch |
| Aug 7, 2025 | Seeking Alpha | The Undercovered Dozen | Harrow, Inc. | Health Care | Drug Manufacturers - Specialty & Generic | Bull | NASDAQ | — | View Pitch |
| Manager Name | Fund Name | Fund AUM | Invested Value | Portfolio Weight | Shares Owned | Shares Bought / Sold During Quarter | % Bought / Sold During Quarter | % of Shares Outstanding Owned |
|---|---|---|---|---|---|---|---|---|
| Neil Kumar | Ikarian Capital | $1.2B | $9.0M | 0.70% | 183,347 | +220,000 | +75.94% | 0.4889% |
| Steven Halverson | Private Capital Management | $1.0B | $90.3M | 8.28% | 1,843,091 | -12,573 | -0.68% | 4.9146% |
| Israel Englander | Millennium Management LLC | $233.2B | $281,799 | 0.00% | 5,751 | -70,494 | -92.46% | 0.0153% |
| Cliff Asness | AQR Capital Management | $190.6B | $377,153 | 0.00% | 7,697 | +57 | +0.75% | 0.0205% |
| James E. Flynn | Deerfield Management | $6.9B | $425,957 | 0.01% | 8,693 | +8,693 | +100.00% | 0.0232% |